IP Library Granted Patent US 9,018,236
Granted Patent B2
US 9,018,236 · App. 13/803,280 · Granted Apr 28, 2015

Cyclodextrin-based microemulsions, and dermatological uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,018,236
App. No.
13/803,280
Granted
Apr 28, 2015
Kind
B2
Abstract

Described herein are cyclodextrin-stabilized microemulsion systems useful for increasing the solubility, stability, bioavailability, or safety of an active agent for delivery to the skin. The microemulsions may reduce the occurrence of skin irritation or odor upon application.

Claims (21)

1. A microemulsion, consisting essentially of: an aqueous phase; a first surfactant; and a second surfactant, wherein the first surfactant is a cyclodextrin, the second surfactant comprises caprylocaproyl macrogol-8 glycerides or caprylocaproyl polyoxyl-8 glycerides, and the aqueous phase comprises a moisturizer or emollient and an anti-inflammatory agent.

2. The microemulsion of claim 1 , wherein the aqueous phase is present in an amount from about 75% to about 95% by weight of the microemulsion.

3. The microemulsion of claim 1 , wherein the moisturizer or emollient is selected from the group consisting of panthenol, allantoin, sodium hyaluraonate, pentylene glycol, and combinations/mixtures thereof.

4. The microemulsion of claim 1 , wherein the moisturizer or emollient is present in an amount from about 0.8% to about 2.3% by weight of the aqueous phase.

5. The microemulsion of claim 1 , wherein the anti-inflammatory agent is niacinamide.

6. The microemulsion of claim 1 , wherein the anti-inflammatory agent is present in an amount from about 0.5% to about 2% by weight of the aqueous phase.

7. The microemulsion of claim 1 , wherein the aqueous phase comprises an antioxidant or preservative.

8. The microemulsion of claim 1 , wherein the antioxidant or preservative is selected from the group consisting of potassium sorbate, sodium benzoate, disodium EDTA, and combinations/mixtures thereof.

9. The microemulsion of claim 1 , wherein the antioxidant or preservative is present in an amount from about 0.2% to about 0.6% by weight of the aqueous phase.

10. The microemulsion of claim 1 , wherein the aqueous phase comprises a pH adjuster.

11. The microemulsion of claim 10 , wherein the pH adjuster is sodium hydroxide.

12. The microemulsion of claim 10 , wherein the pH adjuster is present in an amount from about 0.02% to about 0.1% by weight of the aqueous phase.

13. The microemulsion of claim 1 , wherein the first surfactant is present in an amount from about 1% to about 8% by weight of the microemulsion.

14. The microemulsion of claim 1 , wherein the first surfactant is hydroxypropyl α-cyclodextrin, hydroxypropyl β-cyclodextrin, or hydroxypropyl γ-cyclodextrin.

15. The microemulsion of claim 1 , wherein the first surfactant is hydroxypropyl β-cyclodextrin.

16. The microemulsion of claim 1 , wherein the second surfactant is present in an amount from about 4% to about 22% by weight of the microemulsion.

17. The microemulsion of claim 1 wherein the cyclodextrin is hydroxypropyl β-cyclodextrin, the cyclodextrin is present in an amount of about 5% by weight of the microemulsion; and

the caprylocaproyl macrogol-8 glycerides or caprylocaproyl polyoxyl-8 glycerides, is present in an amount of about 15% by weight of the microemulsion.

18. The microemulsion of claim 1 wherein the cyclodextrin is hydroxypropyl β-cyclodextrin, the cyclodextrin is present in an amount of about 3% by weight of the microemulsion; and

the caprylocaproyl macrogol-8 glycerides or caprylocaproyl polyoxyl-8 glycerides, is present in an amount of about 7% by weight of the microemulsion.

19. A method of making a microemulsion of claim 1 , comprising the step of combining the aqueous phase, the first surfactant, and the second surfactant.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT Recorded Jul 6, 2015
From: ECR PHARMACEUTICALS CO., INC.; PRECISION DERMATOLOGY, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036091/0257 →
RELEASE OF SECURITY INTEREST Recorded Jul 7, 2014
From: GCI CAPITAL MARKETS, LLC
To: PRECISION DERMATOLOGY, INC.
Reel/Frame 033280/0556 →
SECURITY AGREEMENT Recorded Sep 20, 2013
From: PRECISION DERMATOLOGY, INC.
To: GCI CAPITAL MARKETS LLC
Reel/Frame 031249/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2013
From: TRUMBORE, MARK W.; MAJHI, PINAKI RANJAN; SHAH, DINEN DIVYANG
To: PRECISION DERMATOLOGY, INC.
Reel/Frame 030892/0914 →